Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

FB 04 - Universitätsmedizin

Johannes Gutenberg-Universität Mainz

Obere Zahlbacher Str. 63, Geb. 912, 55131 Mainz
  • 06131/17-9704 oder 9799 (Sekretariat)
  • 06131/17-9669
Forschungsprojekte
Ergebnisse pro Seite:  10

2023 - 2040

A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with topotecan for the treatment of patients with small cell lung cancer (DAREONTM-9) (#1508)
  • Dr. JürgenAlt

2023 - 2040

An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors (INSIGHT) (#1493)
  • Dr. JürgenAlt

2023 - 2025

FIT
  • Dr. HakimEchchannaoui,
  • Prof. Dr. NielsHalama,
  • Univ.-Prof. Dr. MatthiasGaida

2023 - 2025

MHC-independent T-cell receptors against the tumor microenvironment
  • Univ.-Prof. Dr. ThomasWölfel,
  • Prof. Dr. RienkOffringa,
  • Univ.-Prof. Dr. MatthiasGaida,
  • Dr. MichaelVolkmar

2023 - 2040

Venetoclax in combination with the BTK inhibitor Ibrutinib and rituximab or conventional chemotherapy (bendamustine) and ibrutinib and rituximab in patients with treatment naïve Mantle Cell Lymphoma not eligible for high dose therapy - The European Mantle Cell Lymphoma Elderly III-Trial (#1281)
  • Univ.-Prof. Dr. GeorgHess

2023 - 2040

A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (#1417)
  • Dr. MariusFried

2023

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases - a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial
  • Dr. IreneSchmidtmann

2023 - 2026

ARTEMIS STUDYProspective, Multi-country, Comparative Observational Study (non-interventional) of clinical outcomes that benefit mHSPC patients treated with Apalutamide + ADT and Enzalutamide+ADT under routine clinical practice (ARTEMISpro)
  • PD Dr. MaximilianBrandt,
  • Dr. AnitaThomas

2023 - 2024

Mikrobiologische Performance Qualification der Robotersysteme APOTECAunit und APOTECAsyringe
  • Prof. Dr. IreneKrämer,
  • Dr. JudithThiesen,
  • DavidAckermann

2023 - 2027

Empowering treatment precision – Nutzung von Tumor-Organoiden zur Verbesserung des klinischen Managements von Kopf- und Halstumor-Patienten
  • Dr. DesireeGül,
  • Dr. AyaKhamis Hassan,
  • Prof. Dr. RolandStauber